Eloxx Pharmaceuticals (ELOX) vs. The Competition Critical Review

Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Free Report) is one of 902 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Eloxx Pharmaceuticals to similar companies based on the strength of its institutional ownership, risk, valuation, profitability, analyst recommendations, dividends and earnings.

Profitability

This table compares Eloxx Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Volatility and Risk

Eloxx Pharmaceuticals has a beta of -1862.26, indicating that its share price is 186,326% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals’ competitors have a beta of -3.17, indicating that their average share price is 417% less volatile than the S&P 500.

Valuation & Earnings

This table compares Eloxx Pharmaceuticals and its competitors revenue, earnings per share (EPS) and valuation.

Eloxx Pharmaceuticals’ competitors have higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for Eloxx Pharmaceuticals and its competitors, as reported by MarketBeat.

Eloxx Pharmaceuticals presently has a consensus price target of $38.33, indicating a potential upside of 155.05%. As a group, “Pharmaceuticals” companies have a potential upside of 28.49%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts clearly believe Eloxx Pharmaceuticals is more favorable than its competitors.

Summary

Eloxx Pharmaceuticals beats its competitors on 7 of the 13 factors compared.

Eloxx Pharmaceuticals Company Profile

(Get Free Report)

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.